10:58 AM EDT, 09/25/2024 (MT Newswires) -- CERo Therapeutics ( CERO ) said Wednesday that Chief Executive and President Brian Atwood, Chief Financial Officer Charles Carter and Chief Technology Officer Daniel Corey have decided to step down from their respective positions.

The company named Vice Chairman Chris Ehrlich as chairman and interim CEO and said Atwood will become a consultant to CERo while remaining on the board.

CERo also said its existing investors have committed a $1.25 million financing, allowing it to work with the US Food and Drug Administration to resolve the remaining investigational new drug application issue for its lead product candidate CER-1236, which is on clinical hold.

The company's shares were up about 17% in recent trading.

Price: 0.11, Change: +0.02, Percent Change: +17.29